Among the major issues of hematology is the lack of donor-derived hematopoietic progenitor cells (HPCs) transplanted for treatment of hematologic diseases and congenital hematopoiesis disorders. Thus, a search of new additional sources of HPCs is needed. It has been shown that human placenta plays an important role in embryonic hematopoiesis [3, 9] . At the same time, the immune phenotype of placental HPCs and their multipotency have not been completely studied as yet. Investigation of placental HPCs and comparison of their properties with the properties of fetal and adult HPCs are important for assessment of their possible clinical application. The purpose of this study has been to compare the phenotypes of HPCs from placenta, umbilical cord blood and fetal liver.
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MATERIALS AND METHODS
Mother's blood was tested for HIV-1/2, HCV, HBV, CMV and Treponema pallidum. Placental tissue was additionally tested for the Chlamidium trachomatis, Mycoplasma genitalis, Ureaplasma urealyticum and Ureaplasma parvum, HSV-1/2, CMV. The umbilical cord was cut; the placenta was purified from amnion and decidua. Placental tissue was minced with sterile scissors into small fragments and intensively washed with Hanks' solution for blood removal. Then the tissue was treated with a 0.2% collagenase I (Serva, Germany), 0.35 mg/ml hyaluronidase (Sigma, USA), 100 U/ml DNase I (Sigma, USA) with 1 mg/ml bovine serum albumin (BSA) within 30-50 minutes at +37 °C. Placental cells were filtered through a 70 micron cell strainer (Becton Dickinson, USA). At the 2nd stage tissue was incubated with a fresh portion of the enzymes for 30-60 minutes at +37 °C. After fermentation cells were washed in phosphate buffered saline (PBS) with 1 mg/ml BSA. Mononuclear cells from placenta and umbilical cord blood were isolated using a Ficoll density centrifugation method (1.077 g/ml) (Biochrome, Germany), twice washed, and filtered through a 40 micron cell strainer. Cord blood mononuclear cells were treated with a mixture of such enzymes as placenta tissue for 50 min at 37°C and were washed in PBS with 1 mg/ml BSA.
OBTAINING OF CELLS FROM FETAL LIVER
The source of the fetal liver was aborted human embryos 5-12 weeks of gestation obtained after voluntary pregnancy termination according to the women's informed consent. Fetal liver cells were obtained by nonenzymatic method. They were obtained by homogenization in the Potter homogenizer in Hanks' solution, followed by filtration through a 100 microns cell strainer. Cryopreservation of liver cells was conducted by a three-stage program according to the method of Lobyntseva G. S. [1] . The samples were stored in liquid nitrogen at -196°C. Fetal liver cells were thawed in a water bath at +40°C. , were present in the placental tissues, cord blood, and fetal liver (Fig. 1, a-c in the placental tissue as well as in the cord blood were positive for CD133 (Fig. 1, d) low/-was present in the placental tissue, but at the same time it was practically not observed in the cord blood and fetal liver (Fig. 1, a-c) .
FLOW CYTOMETRY
The and CD19 expressions were increasing along with the reducing of the CD34 expression level on CD45 low/-cells of placental tissue and cord blood (Fig. 2) .
In contrast to cord blood and fetal liver, the placenta also contained CD34 +/low CD45 + cells. This population was characterized by a high expression level of linear markers compared to the population with a lower expression of CD45 and a higher level of CD34. The frequency of CD14 and CD33 on CD34 +/low
CD45
+ cells was 73.5 % (54.2-88.4%, n = 4). The level of CD19 and CD7 expression in the same population was 14.2% (8.4-21.2%, n = 4) and 3% (1.4-5.2%, n = 4), respectively. Moreover, we noted that the number of myeloid progenitors (CD14 + CD33 + ) were higher among placental HPCs with a higher level of CD45 and lower level of CD34 (Fig. 3) .
The 
low/-, they do not express CD133 stem cell marker and have heterogeneous morphology. The absence of such cells in the cord blood and fetal liver is indicative of their possible formation in the placental (CD2, CD10, CD14, CD15, CD16, CD19, glycophorin) . CD34 hi cells support prolonged B-lymphopoiesis and myelopoiesis in vitro and initiate T, B and myeloid repopulation of human tissues implanted in SCID mice [6] . In the mature bone marrow CD34 expression decreases along with the maturing of cells and increases during of CD38 expression [10] . It was shown that fetal liver contains cells with high level of CD34, and they also express 
